CLINICAL_TRIALS
withdrawal
· 2011-10-10
Clinical Trial Update: Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors [Phase 2]
Summary
A Phase 2 trial of zalutumumab in non-small cell lung cancer patients refractory to tyrosine kinase inhibitors has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Genmab | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: WITHDRAWN